A Phase I, Multicenter, Open-Label First in Human Study of Anti-CEACAM5 Antibody Drug Conjugate M9140 in Participants With Advanced Solid Tumors (PROCEADE-CRC-01)
OPEN TO ACCRUAL
I
NCT05464030
rimini.breakstone@BrownHealth.org
